These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21819807)

  • 1. [Evidence-based therapeutic drug monitoring of lopinavir].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):231-8. PubMed ID: 21819807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evidence-based therapeutic drug monitoring for indinavir].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):239-46. PubMed ID: 21819808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):231-8. PubMed ID: 27393203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evidence-based therapeutic drug monitoring for saquinavir].
    Muret P; Solas C;
    Therapie; 2011; 66(3):207-12. PubMed ID: 21819804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence-based therapeutic drug monitoring of atazanavir].
    Solas C; Muret P;
    Therapie; 2011; 66(3):213-9. PubMed ID: 21819805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?
    Ribera E; López-Cortés LF; Soriano V; Casado JL; Mallolas J
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():41-67. PubMed ID: 16373004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evidence-based therapeutic drug monitoring for nevirapine].
    Muret P; Piedoux S; Solas C; Quaranta S;
    Therapie; 2011; 66(3):187-95. PubMed ID: 21819802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
    Bierman WF; van Vonderen MG; Veldkamp AI; Burger DM; Danner SA; Reiss P; van Agtmael MA
    Antivir Ther; 2011; 16(5):647-55. PubMed ID: 21817186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment.
    Bouillon-Pichault M; Jullien V; Azria E; Pannier E; Firtion G; Krivine A; Compagnucci A; Taulera O; Finkielsztejn L; Chhun S; Pons G; Launay O; Treluyer JM
    J Antimicrob Chemother; 2009 Jun; 63(6):1223-32. PubMed ID: 19389715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.
    Hills-Nieminen C; Hughes CA; Houston S; Shafran SD
    Ann Pharmacother; 2009 Dec; 43(12):2117-20. PubMed ID: 19934385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of lopinavir in HIV/HCV coinfected patients with advanced liver disease.
    Casado JL; Del Palacio M; Moya J; Rodriguez JM; Moreno A; Perez-Elías MJ; Belso A; Dronda F; Moreno S
    HIV Clin Trials; 2011; 12(5):235-43. PubMed ID: 22180521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
    Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
    J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
    Fayet-Mello A; Buclin T; Guignard N; Cruchon S; Cavassini M; Grawe C; Gremlich E; Popp KA; Schmid F; Eap CB; Telenti A; Biollaz J; Decosterd LA; Martinez de Tejada B; ;
    Antivir Ther; 2013; 18(2):171-82. PubMed ID: 22914504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
    Manavi K; McDonald A; Al-Sharqui A
    AIDS; 2007 Mar; 21(5):643-5. PubMed ID: 17314527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
    Marcelin AG; Cohen-Codar I; King MS; Colson P; Guillevic E; Descamps D; Lamotte C; Schneider V; Ritter J; Segondy M; Peigue-Lafeuille H; Morand-Joubert L; Schmuck A; Ruffault A; Palmer P; Chaix ML; Mackiewicz V; Brodard V; Izopet J; Cottalorda J; Kohli E; Chauvin JP; Kempf DJ; Peytavin G; Calvez V
    Antimicrob Agents Chemother; 2005 May; 49(5):1720-6. PubMed ID: 15855487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults.
    van der Leur MR; Burger DM; la Porte CJ; Koopmans PP
    Ther Drug Monit; 2006 Oct; 28(5):650-3. PubMed ID: 17038880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.